Opko Health (XCY) AI Stock Analysis

Company Guidance

OPKO withdrew its consolidated full year guidance for total revenue and costs; for the fourth quarter, it expects total revenue from continuing operations of $62 million to $72 million, including product revenue of $41 million to $46, licensing, collaboration and other revenue of $21 million to $27 million, including Pfizer gross profit share of $12.5 million to $15 million and BARDA funding of approximately $3 million to $5 million, total costs and expenses of $100 million to $105 million, including R&D expense of $32 million to $35 million, depreciation and amortization expense of approximately $19 million, and a loss from discontinued operations of approximately $40 million or approximately $0.05 per share; for the full year, it expects continuing-operations revenue of approximately $268 million to $278 million, including product revenue of $164 million to $169 million, licensing, collaboration and other revenue of $105 million to $110 million, including Pfizer's gross profit share of $34 million to $37 million and total BARDA funding of $20 million to $22 million, costs and expenses of $390 million to $395 million, including R&D expense of $125 million to $130 million, and depreciation and amortization expense of approximately $75 million; BioReference sale-related costs are expected to be approximately $125 million between the fourth quarter of 2026 and completion of the TSA, which is expected to continue for approximately 1 year after closing, and investing $100 million into operations is described as not an unreasonable annual number to think about.